

UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

N

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 Address:

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	I	ATTORNEY DOCKET NO.
09/529,537	06/19/00	IVERSEN	, L	P24.002USA
			EXAMINER	
		HM12/0829		₹,
ALEXIS BAR	RON		CHOT	F. ,
SYNNESTVED	T & LECHNER		ART UNIT	PAPER NUMBER
2600 ARAMA	RK TOWER			(
1101 MARKE	T STREET		1616	
PHILADELPHIA PA 19107-2950		·2950	DATE MAILED:	:
				08/29/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant(s)				
Office Action Summary		09/529,537	IVERSEN, LESLIE LARS				
		Examiner	Art Unit				
		Frank I Choi	1616				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE N - Exten after: - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.13 GIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, exply received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tin within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1)	Responsive to communication(s) filed on						
2a)□		— · is action is non-final.					
3)□	<u>, </u>						
Dispositi	on of Claims						
4)	Claim(s) 1,2,21-38 is/are pending in the applic	eation.					
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1,2 and 21-38</u> is/are rejected.							
7)	7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
	nder 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)[☑ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>7</u> .	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/529,537

Art Unit: 1616

DETAILED ACTION

Claim Objections

Claims 2, 21-37 are objected to because of the following informalities:

Dependent claims should begin with a "The" not an "A".

In claim 21 the proper language for a markush group should be "selected from the group consisting of . . . and" and, if necessary, "and mixtures, thereof" or "at least one" to represent that mixtures of the members of the markush group is possible.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. In the present instance, claim 24 recites the broad recitations and than gives examples which are the narrower statement of the range/limitation.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 09/529,537

Art Unit: 1616

Claims 1, 2, 21-38 are rejected under 35 U.S.C. 103(a) as being unpatentable over GB 1 594 039 in view of Patel et al., EP 0 222 614 and EP 0 391 369.

GB 1 594 039 teaches the combination of opoids and CCK antagonists (See entire document).

Patel et al. teach that CCK antagonists, such as devazepide, are poorly water soluble (Pg. 947).

EP 0 222 614 teaches a gelatin capsule containing a hydrophobic carrier matrix and a hydrophilic substance (pg. 2, lines 47-52) which can create channels in the hydrophobic carrier matrix (pg. 2, lines 62-pg. 3, line 14). It is taught that the hydrophobic carrier matrices contain glycerides and partial glycerides (Pg. 3, lines 9, 10).

EP 0 391 369 teaches pharmaceutical compositions of hydrophobic drugs in the form of oil-in-water emulsions having long term stability (Pg. 1, lines 1-3). It is taught that lipophilic drugs include benzodiazepines and morphine (Pg. 8, claims 21, 25).

Examiner takes official notice that one of ordinary skill in the art would recognize the dosage forms suitable for injection would have to be of appropriate pH and tonicity in order to prevent damage to blood cells and tissue cells at the site of injection.

The difference between the prior art and the claimed invention is that the prior art does not expressly disclose the combination of opioid, CCK antagonist in a biphasic carrier.

However, the prior art amply suggests the same as the combination of opioid and CCK antagonist is well known in the art and the use of biphasic carriers are well known in the art. As such, it would have been well within the skill of and one of ordinary skill in the art would have been motivated to modify the prior art so as to formulate a pharmaceutical formulation which

Application/Control Number: 09/529,537

Art Unit: 1616

can incorporate both lipophilic and hydrophilic drugs, and increase solubility and/or bioavailabilty of the same.

Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references.

Conclusion

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or (703) 305-3592.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Choi whose telephone number is (703) 308-0067.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. José Dees, can be reached on (703) 308-4628.

FIC

August 27, 2001

JOHN PAK PRIMARY EXAMINER GROUP 1000

Ma do